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We determined estimated incidence of and risk fac-
tors for community-associated Clostridium difﬁ  cile infection 
(CA-CDI) among patients treated at 6 North Carolina hos-
pitals. CA-CDI case-patients were deﬁ  ned as adults (>18 
years of age) with a positive stool test result for C. difﬁ  cile 
toxin and no hospitalization within the prior 8 weeks. CA-
CDI incidence was 21 and 46 per 100,000 person-years 
in Veterans Affairs (VA) outpatients and Durham County 
populations, respectively. VA case-patients were more likely 
than controls to have received antimicrobial drugs (adjusted 
odds ratio [aOR] 17.8, 95% conﬁ  dence interval [CI] 6.6–48] 
and to have had a recent outpatient visit (aOR 5.1, 95% CI 
1.5–17.9). County case-patients were more likely than con-
trols to have received antimicrobial drugs (aOR 9.1, 95% CI 
2.9–28.9), to have gastroesophageal reﬂ  ux disease (aOR 
11.2, 95% CI 1.9–64.2), and to have cardiac failure (aOR 
3.8, 95% CI 1.1–13.7). Risk factors for CA-CDI overlap with 
those for healthcare-associated infection. 
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C
lostridium difﬁ  cile is an anaerobic spore-forming 
gram-positive bacillus that produces exotoxins that are 
pathogenic to humans. C. difﬁ  cile is known to infect persons 
receiving antimicrobial drug therapy, older and severely ill 
patients who are hospitalized, or residents of long-term 
care facilities. C. difﬁ  cile infection (CDI) is manifested as 
as diarrhea, pseudomembranous colitis, and, occasionally, 
toxic megacolon or even death. Recent reports suggest an 
increasing incidence and severity of CDI (1–3) that may 
be related to the emergence of a hypervirulent strain (4–6). 
In addition, reports have been published of CDI emerging 
in persons previously thought to be at low risk, including 
otherwise healthy persons in the community (7–9).
Community-associated or -acquired CDI (CA-CDI) 
was ﬁ  rst reported in 1984 by Stergachis et al. (10) who 
found that the attack rate of CA antimicrobial drug–associ-
ated colitis requiring hospitalization was 1.4/100,000 pop-
ulation. In a review by Riley et al. (11) of 580 C. difﬁ  cile 
toxin–positive stool samples submitted from patients with 
diarrhea and a clear history of recent (<4 weeks) antimicro-
bial drug exposure, 10.7% were from patients who did not 
have a recent history of hospitalization. Additional reports 
indicated incidences from 7.7–12.2 cases of CA-CDI per 
100,000 persons in US communities (7,12) to 25 primary 
episodes per 100,000 persons per year in Sweden (8). In 
December 2005, the US Centers for Disease Control and 
Prevention (CDC) reported a series of severe CDI cases 
in populations previously considered at low risk, including 
generally healthy persons living in the Philadelphia, Penn-
sylvania, USA, area (13).
In January 2006, CDC was notiﬁ  ed by a regional Vet-
erans Affairs (VA) hospital in North Carolina that surveil-
lance conducted from October 2004 through December 
2005 indicated that 35% of patients with CDI experienced 
onset of disease in the community. Fewer than 10% of 
these patients had stayed overnight in a healthcare facility, 
and only half had received antimicrobial drugs in the previ-
ous 2 months (14). In response to apparent emerging CDI 
in the community, CDC was invited by the North Carolina 
Department of Health and Human Services to investigate 
these ﬁ  ndings and to recommend control measures.
We retrospectively identiﬁ  ed cases of CA-CDI in 4 
North Carolina VA hospitals and all hospital catchments in 
Durham County, North Carolina, to determine the estimat-
ed incidence in each population. In addition, we assessed 
risk factors for CA C. difﬁ  cile disease using case–control 
methods.
Methods
Settings and Case Finding
Data were collected from 6 North Carolina hospitals, 
including the Durham VA hospital, 2 other local hos-
pitals, and 3 other VA hospitals located throughout the 
state. This activity was determined by CDC not to be hu-
man subject research; thus, human subject regulations did 
not apply.
Case ﬁ  nding involved reviewing positive C. difﬁ  cile 
toxin assays from the VA infection control database, Com-
puter Patient Record Systems, and the surveillance data-
base of the Duke University Hospital network. Medical and 
laboratory records were retrospectively reviewed for case-
patients from January through December 2005. Trained 
coders abstracted data from electronic and paper medical 
records using standardized forms. Data collected included 
demographics, signs and symptoms at the time of admis-
sion, laboratory results, prior hospitalization, risk factors, 
treatments, and outcomes.
Case Deﬁ  nitions
A CDI case-patient was deﬁ  ned as a person >18 years 
of age with a nonformed (i.e., taking the shape of the con-
tainer) stool specimen with positive test results for C. dif-
ﬁ  cile toxin. If the case-patient had a previous C. difﬁ  cile–
positive stool test results within the 8 weeks preceding the 
collection date, he or she was excluded. All laboratories 
used the same toxin enzyme immunoassay (C. DIFFICILE 
TOX A/B II; TECHLAB, Blacksburg, VA, USA). CDI cas-
es were further categorized according to when and where 
the stool specimen was collected, as community onset, CA, 
or inpatient healthcare exposure. We deﬁ  ned community 
onset as occurring 1) in an outpatient setting; 2) <3 calendar 
days after hospital admission; or 3) 4–5 calendar days after 
admission and with diarrhea documented <3 days after hos-
pital admission. CA-CDI was deﬁ  ned as community-onset 
CDI for which there was no inpatient healthcare exposure 
within 8 weeks before the stool collection date. Inpatient 
healthcare exposure was deﬁ  ned as admission to an acute-
care hospital or long-term care facility that provided skilled 
nursing care to the patient for >1 overnight stay. 
We excluded CDI case-patients whose medical records 
appeared incomplete for determination of disease catego-
rization; these case-patients were classiﬁ  ed as unknowns. 
Community-onset CDI case-patients who were seen at 
Durham County hospitals but who resided outside the state 
were excluded because of frequent gaps in data necessary 
to determine the date of their last discharge from a health-
care facility and because their data could not contribute to 
the county population incidence. Among CA-CDI case-pa-
tients, ambulatory patients with a history of bone marrow 
transplant (BMT) or end-stage renal disease (ESRD) were 
excluded because of their intensive outpatient healthcare 
exposures. In addition, all prisoners were excluded. Al-
though included in the incidence estimation, patients with 
inﬂ  ammatory bowel disease and chronic diarrhea were ex-
cluded from the case–control study because they are rec-
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ognized populations at increased risk for CDI and because 
their disease symptoms are difﬁ  cult to differentiate from 
the symptoms of CDI (15–17).
We interviewed a subset of case-patients to conﬁ  rm 
and expand information available from medical records 
pertaining to previous inpatient healthcare exposures and 
medication histories. We also surveyed physicians in Dur-
ham County to assess perceptions regarding the frequency 
and severity of CDI in the community and to determine 
laboratories used for C. difﬁ  cile diagnostic testing. This 
survey included physicians working in emergency depart-
ments and in family medicine, internal medicine, obstetrics 
and gynecology, infectious diseases, gastroenterology, and 
urgent care practices. We also contacted other academic in-
stitutions and laboratories in nearby counties to determine 
whether our case ﬁ  nding was comprehensive.
VA Case–Control Study
We conducted an unmatched 1:3 case–control study 
of VA CA-CDI case-patients using controls chosen from 
among VA outpatients randomly selected from VA out-
patient clinics seen at the 4 facilities on 4 random dates 
distributed throughout 2005. Exclusion criteria for controls 
included a documented clinical diagnosis of diarrhea or a 
stool test result positive for C. difﬁ  cile toxin in 2005, a his-
tory of inpatient healthcare exposure in the prior 8 weeks, 
or a history of ESRD. Similar data were collected for the 
controls as for case-patients, except for prior hospitaliza-
tion within 8 weeks.
We attempted phone interviews of all the VA CA-CDI 
case-patients, but not the controls, regarding their admis-
sion, symptoms, and medications. To overcome the limi-
tation of recall bias, we reviewed electronic records after 
asking case-patients if they received their medications 
only from the VA (where electronic records were then re-
viewed) or whether they ever (also) obtained prescriptions 
from non-VA providers. All case-patient interviews were 
completed by the ﬁ  rst quarter of 2006.
Durham County Case–Control Study
We conducted a case–control study at the 2 major 
hospitals serving Durham County residents. Controls were 
randomly selected from the county voter registration list; 
we made 3 attempts to reach residents by phone and elicit 
their participation. Exclusion criteria for controls included 
a history of inpatient healthcare exposure or diarrhea in 
the year 2005, ESRD, or BMT. We also performed phone 
interviews on a convenience sample of case-patients. All 
interviews were completed by December 2006.
Data Analysis
Data for the case characterization and case–control 
study were entered into Microsoft Ofﬁ  ce Access 2003 (Mi-
crosoft Corp., Redmond, WA, USA). Data checks were 
performed and double entries were removed. Incidence 
was estimated for the North Carolina VA hospital catch-
ments by dividing the number of CA-CDI case-patients by 
all veterans registered for outpatient services at the 4 VA 
facilities in 2005 per 100,000 person-years. An estimate of 
the Durham County population-based rate was determined 
by dividing the number of CA-CDI case-patients from Dur-
ham County (including VA case-patients who resided in 
the county) by the 2005 adult (>18 years of age) population 
census per 100,000 person-years.
Multivariable analysis was performed by using SAS 
version 9.1 (SAS Institute Inc., Cary, NC, USA) and step-
wise logistic regression. Signiﬁ  cant variables based on the 
univariate analysis (p<0.05) were included in the multi-
variable model. We used the Hosmer and Lemeshow and 
the residual χ2 goodness-of-ﬁ  t tests. We estimated adjusted 
prevalence odds ratios (aORs) with 95% conﬁ  dence inter-
vals (CIs) from the regression procedure.
Results
Of the 1,046 CDI case-patients identiﬁ  ed from the 6 
study facilities from January through December 2005, 426 
(40.7%) were community-onset (Figure). A total of 214 
community-onset CDI case-patients were excluded; 94 had 
inpatient healthcare exposures within the 8 weeks prior to 
positive toxin assay, 29 had ESRD, 20 were from out of 
state, 17 were BMT patients, 8 were prisoners, and 46 had 
an unknown status regarding prior inpatient healthcare ex-
posures. The 212 case-patients with CA-CDI represented 
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Total CDI cases, N = 1,046
Community-onset,
n = 426 (41.0%)
Community-associated
 n = 212 (49.5%)
Unknown exposure, n = 46
VA 
n = 36
Non-VA
n = 136
Excluded: IBD/chronic diarrhea, n = 40
Durham
n = 73
Excluded, n = 168
Excluded: 
inadequate 
medical 
information, 
n = 63
Hospital-onset, n = 620
Figure. Categorization of Clostridium difﬁ  cile infection (CDI) cases 
from 6 hospitals, North Carolina, 2005. IBD, irritable bowel disease; 
VA, Veterans Affairs hospital.RESEARCH
49.5% of all cases of community-onset CDI and 20% of 
overall cases of CDI.
The estimated incidence of CA-CDI in the VA catch-
ments and county adult population was 21 and 46 per 
100,000 persons per year, respectively (Table 1). Among 
men in the VA and in Durham County, those 45–64 years 
of age had a higher incidence than those 18–44 and >64 
years of age combined (p<0.05). Overall, incidence was 
higher among county female case-patients than male case-
patients (62 vs. 28/100,000 persons per year, respectively; 
p = 0.0005).
Characteristics of CA-CDI Cases
A total of 109 CA-CDI case-patients were found among 
VA catchments or Durham County residents for whom full 
case-characteristics were available after exclusion criteria 
(Figure). The characteristics of CA-CDI case-patients are 
described in the online Appendix Table (www.cdc.gov/
EID/content/16/2/197-appT.htm). We did not compare the 
2 populations.
Nineteen case-patients in the VA catchments and 12 
case-patients from Durham County had histories of hospi-
talization >8 weeks prior to symptom onset; medians were 
33 weeks (range 10–84) and 34 weeks (range 9–92), respec-
tively. The remaining case-patients had no recorded history 
of previous hospitalization. Median time from symptom 
onset to testing was 1 week (range 1 day–9 weeks).
Overall, 58% of case-patients in each population were 
admitted around the time of their CDI diagnosis, for a me-
dian duration of 1 week (maximum 3 and 5 weeks, Durham 
County and VA catchments, respectively). Diarrhea was 
the most common sign or symptom, followed by abdominal 
pain and vomiting. Among potential exposures, >50% of 
case-patients in each population had >1 outpatient visit in 
the 3 months before the test date. Overall, 53 case-patients 
(49%) did not have exposure to antimicrobial drugs in the 
3 months prior to the test date. Among those who had re-
cently received antimicrobial drug therapy, pencillins and 
quinolones were most commonly reported.
Case-patient Interview 
We interviewed 22 VA and 31 county (non-VA hos-
pital) resident CA-CDI case-patients. Only 2 (4%) of the 
53 patients interviewed were reclassiﬁ  ed as other than CA-
CDI on the basis of interview ﬁ  ndings: 1 had a history of 
CDI 2 months before the index episode, and 1 was newly 
identiﬁ  ed as an ESRD patient. Of the remaining intervie-
wees, 25 were able to provide information on whether they 
had been exposed to antimicrobial drugs. Of the 11 inter-
viewees whose medical records suggested no exposure to 
antimicrobial drugs within the past 3 months, 5 (45%) re-
ported taking antimicrobial drugs during this time. These 
included 3 from the VA who indicated that they received 
all their medications from the VA; however, their electron-
ic medical records did not have documentation of recent 
antimicrobial drug prescriptions.
Case–Control Study at VA
Case-patients and controls were similar with regard to 
age, sex, and race (Table 2). Over the 3 months before CDI 
onset, exposure to antimicrobial drugs (OR 19.6, 95% CI 
7.6–51, p<0.0001), antimotility medications (OR 6.6, 95% 
CI 1.2–37.8, p<0.05), and outpatient visits (OR 6.1, 95% 
CI 2–18.6, p<0.05) were most strongly associated with 
case status. Among antimicrobial drugs, exposure to peni-
cillins and quinolones were signiﬁ  cant. In the multivariable 
analysis, antimicrobial drug use with an aOR of 17.8 (95% 
CI 6.6–48, p<0.0001) and outpatient visits (aOR 5.1, 95% 
CI 1.5–17.9, p<0.05) were signiﬁ  cant risk factors.
Case–Control Study in Durham County 
Information was obtained for all 73 case-patients but 
only for 48 controls (Table 3). The case-patients and con-
trols were similar with regard to age, sex, and race. Among 
potential exposures during the previous 3 months, exposure 
to antimicrobial drugs (OR 3.9, 95% CI 1.6–0.5, p<0.05) 
was most strongly associated with case status. In the multi-
variable analysis, antimicrobial drug use (aOR 9.1, 95% CI 
2.9–28.9, p<0.05), gastroesophageal reﬂ  ux disease (GERD) 
(aOR 11.2, 95% CI 1.9–64.2, p<0.05), and cardiac failure 
(aOR 3.8, 95% CI 1.1–13.7, p<0.05) were independent risk 
factors.
Physician Survey
Of 33 Durham County primary care and relevant spe-
cialty medicine practices surveyed, 59 physicians from 16 
(48.5%) practices responded. Only 2 commercial laborato-
ries, in addition to the 2 Durham hospital laboratories, were 
used for diagnostic testing of C. difﬁ  cile in the outpatient 
setting. One laboratory was unable to provide any informa-
tion regarding positive C. difﬁ  cile tests performed on per-
sons living in Durham County, whereas the other laborato-
ry had 14 positive C. difﬁ  cile test results for this population 
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Table 1. Estimated incidence of community-associated 
Clostridium difficile infection per 100,000 persons among VA and 
Durham County populations, North Carolina, USA, 2005* 
Age group, y, no. cases 
Population 18–44 45–64 >65 Overall
VA
 M  14.7 28.5† 15.9 20.8
Durham County 
 M  11.0 56.6† 57.5 28.4
 F  21.9 70.4 204.6 61.9‡
Overall 16.5 63.9 146.4 46.0
*VA, Veterans Affairs. 
†p<0.05 when compared with age groups 18–44 and >65 y combined. 
‡p<0.005 when compared with men from Durham County. Community-associated C. difﬁ  cile
during 2005. Additional information about these cases was 
unavailable.
Discussion
We found that 20% of all CDI cases were CA, simi-
lar to the 22%–28% found in previous studies conducted 
in Sweden (8,18). We are not aware of previous studies 
from the United States that determined the proportion 
of CA-CDI from all CDI cases. However, available lit-
erature on the incidence of CA-CDI in the United States 
(7,13,19) reports lower rates than what we found in the 
VA (21/100,000 persons/year) and Durham County 
(46/100,000 persons/year) catchments. The annual inci-
dence in Philadelphia in 2005 (7.6/100,000 persons/year) 
and the incidence in Connecticut in 2006 (6.9/100,000 
persons/year) were based on passive, voluntary reports 
of CA-CDI in mostly healthy persons and thus likely un-
derestimated the true incidence and spectrum of disease 
(13,19). However, a recent active case-ﬁ  nding study for 
CA-CDI conducted in the United Kingdom (20) suggested 
rates of 20–30 per 100,000, similar to the studies conduct-
ed in Sweden (8,18). Furthermore, a recent study from 
Manitoba, Canada, found that ≈20% of CDI cases were 
CA, and annual incidence was ≈20/100,000 (21). Ap-
parent differences in the incidence of CA-CDI likely re-
ﬂ  ect differences both in study approaches and population 
characteristics. Nonetheless, CA-CDI should be consid-
ered a serious public health concern in need of further un-
derstanding and improved surveillance. Although it is un-
clear why the estimated incidence rates in Durham County 
are the highest for CA-CDI reported, recent evidence in-
dicate that the rates in the county may have since declined 
(22), a phenomenon anecdotally experienced in other lo-
cations in the southeastern United States (R.P. Gaynes, 
pers. comm.) (23).
The incidence rate we found was highest for the 45–64 
years of age category (28.5/100,000) for the VA catch-
ments. In Durham County, men 45–64 years of age had 
a higher rate than other those in age categories combined 
(p<0.05). This ﬁ  nding is notable because CDI is usually 
associated with older patients (9,19). Women had a higher 
rate than males in the community (62 vs. 28 cases/100,000 
persons/year, respectively; p = 0.0005), as was also recent-
ly noted in a report from Connecticut (19). Although some 
data suggest an increased risk for multiple CDI recurrences 
in healthy women (24) and recent reports have noted severe 
CDI in pregnant women (25), female gender has not been 
previously a well-documented risk factor for CDI.
Previous reports have shown that an age >65 years is 
a risk factor for hospital-onset CDI (2,26,27). In compari-
son, the median age of the case-patients in this community 
appeared to be younger, 61 years in Durham County and 
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Table 2. Results of community-associated Clostridium difficile infection case–control study, Veterans Affairs, North Carolina, USA, 
2005* 
No. (%) persons 
Characteristic  Case-patients, n = 36  Controls, n = 108  OR (95% CI) 
Demographics      
  Median age, y (range)  62 (38–85)  64 (36–86)   
  Female gender  4 (11)  4 (4)   
  Non-Hispanic white race  25 (69)  70 (65)   
Coexisting health conditions       
  Hypertension  16 (44)  75 (69)  0.35 (0.2–0.8)†
 
  Cardiac failure  6 (17)  5 (5)  4.1 (1.2–14.4)†
 
Exposures‡      
  Outpatient visit  32 (89)  69 (57)  6.1 (2.0–18.6)†
 
  Antimicrobial drugs  24 (66)  10 (9)  19.6 (7.6–51.0)†
 
    Penicillins  13 (36)  3 (3)  19.8 (5.2–75.1)§
 
    Quinolones  6 (17)  3 (3)  7 (1.7–29.7)†
 
   NSAIDs  6 (17)  30 (28)  0.5 (0.2–0.4) 
   Antimotility medications  4 (11)  2 (2)  6.6 (1.2–37.8)†
 
   Gastric acid suppressors  18 (50)  37 (34)  1.9 (0.9–4.1) 
  H2 blockers  7 (19)  13 (12)  1.8 (0.6–4.8) 
  Proton pump inhibitors  13 (36)  26 (24)  1.7 (0.7–4.0) 
  Steroids  4 (11)  3 (3)  4.4 (0.9–20.5) 
Multivariable analysis¶
      
  Antimicrobial drugs      17.8 (6.6–48.0)#
 
  Outpatient visit      5.1 (1.5–17.9)†# 
*OR, odds ratio; CI, confidence interval; NSAIDs, nonsteroidal antiinflammatory drugs. 
†p<0.05. 
‡Exposures among case-patients and controls were within 3 months prior to the test date. 
§p< 0.0001. 
¶Goodness-of-fit tests: residual Ȥ
2, p = 0.33; Hosmer and Lemeshow, p = 0.12. 
#Adjusted OR. RESEARCH
63 years in VA. In addition, the proportion and severity of 
fever, leukocytosis, and renal insufﬁ  ciency for our case-pa-
tients were lower (26,28,29). No case-patients were admit-
ted to the intensive care unit for CA-CDI, and none under-
went colectomy. One case-patient in each population died 
within 10 days of diagnosis, and the death was attributable 
to CDI. Nonetheless, 15% had disease severe enough to re-
quire a visit to the emergency department, and another 59% 
required hospital admission for CDI management.
Antimicrobial drug exposure has long been known 
as a risk factor for healthcare-associated CDI. However, 
among CA cases in our study, 49% were not exposed to 
antimicrobial drugs. This percentage was slightly higher 
than the recent ﬁ  ndings from Philadelphia (13) and Con-
necticut (19), where 24% and 36%, respectively, were 
not exposed to antimicrobial drugs. In contrast, Dial et al. 
found the absence of antimicrobial drug exposure >90 days 
to range from 60% to 70% (30). However, their analysis 
was limited to a clinical research database in which some 
hospitalization and antimicrobial drug exposures may not 
have been included. Two prospective studies have recently 
been conducted in the community. Bauer et al. (31) found 
that 42% of CA-CDI case-patients had not been exposed to 
antimicrobial drugs during the prior 6 months, and Wilcox 
et al. (20) found that 84% case-patients had not received 
antimicrobial drugs during the month before C. difﬁ  cile de-
tection. One hypothesis to explain the absence of antimi-
crobial drug exposure is that there are unmeasured factors 
affecting the epidemiology of CDI. For example, remote 
antimicrobial drug exposure, or exposure to other medica-
tions with antimicrobial activity, may be increasing the risk 
of disease; alternatively, increased awareness of CDI may 
be leading to increased testing and documentation of C. dif-
ﬁ  cile in patients not previously tested. Another possibility 
is that strains with new virulence properties (e.g., binary 
toxin) that enable disease in the absence of prior antimi-
crobial drug use have emerged. Despite antimicrobial drug 
exposure being absent in many patients, we found that this 
exposure remained the most important modiﬁ  able risk fac-
tor for CA-CDI.
Additional risk factors included markers of chronic 
disease such as outpatient visits in the VA population and 
GERD and cardiac failure in the county population. In 
the VA population, frequent outpatient visits could reﬂ  ect 
transmission in ambulatory care settings and could be a 
marker of a more severe underlying disease. Unlike other 
recent studies (9), we did not ﬁ  nd proton pump inhibitors 
or H2 blockers were a major risk factor for CA-CDI. How-
ever, the ﬁ  nding of GERD as a risk factor suggests the pos-
sibility that undocumented use of over-the-counter proton 
pump inhibitors could have increased risk in these patients. 
Alternatively, there may be factors in the pathogenesis of 
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Table 3. Results of community-associated Clostridium difficile infection case–control study, Durham County, North Carolina, USA, 
2005* 
No. (%) persons 
Characteristics  Case-patients, n = 73  Controls, n = 48  OR (95% CI) 
Demographics      
  Median age, y (range)  61 (20–101)  55 (22–87)   
  Female gender  57 (58)  34 (71)   
  Non-Hispanic white race    34 (47)  35 (73)  0.32 (0.12–0.7)†
 
Coexisting health conditions       
  Cardiac failure  20 (27)  5 (10)  3.24 (1.12–9.4)†
 
  GERD  20 (27)  2 (4)  8.7 (1.9–39.1)†
 
  Hypertension  36 (49)  13 (27)  2.6 (1.2–5.7)†
 
Exposures‡      
  Antimicrobial drugs  32 (44)  8 (17)  3.9 (1.6–9.5)†
 
  NSAIDs  13 (17.8)  24 (50)  0.2 (0.1–0.5)†
 
  Gastric acid suppressors  15 (21)  5 (10)  2.2 (0.75–6.6) 
  H2 blockers  6 (8)  3 (6)  1.3 (0.3–5.6) 
  Proton pump inhibitor  9 (12)  2 (4)  3.2 (0.7–15.7) 
  GERD  20 (27)  2 (4)  8.7 (1.9–39.1)† 
Multivariable analysis§
      
  Antimicrobial drugs      9.1 (2.9–28.9)†¶
 
 NSAIDs      0.2  (0.1–0.5)†¶
 
 GERD      11.2  (1.9–64.2)†¶
 
  White race      0.2 (0.05–0.40)†¶
 
  Cardiac failure      3.8 (1.1–13.7)†¶ 
*OR, odds ratio; CI, confidence interval; GERD, gastroesophageal reflux disease; NSAIDs, nonsteroidal antiinflammatory drugs. 
†p<0.05. 
‡Exposures among case-patients were within 3 months prior to the test date; exposures for controls were for all of 2005. 
§Goodness-of-fit tests: residual Ȥ
2, p = 0.38; Hosmer and Lemeshow, p = 0.77.  
¶Adjusted OR. Community-associated C. difﬁ  cile
GERD that increases the risk for CDI.
Our study has several limitations. First, it is likely 
that there was incomplete case ascertainment, especially 
in those who underwent testing by outside laboratories so 
that, as high as these population incidence estimates are, 
they are likely underestimates of the true incidence. How-
ever the degree of underestimate is less likely in the VA 
system as there is ﬁ  nancial incentive for patients to undergo 
testing within the system. The community physician survey 
conducted in Durham County indicated that there were 2 
commercial laboratories other than Durham hospital labo-
ratories used for testing. Although we were unable to deter-
mine the number of C. difﬁ  cile tests performed at 1 labora-
tory, only 14 case-patients were identiﬁ  ed from the other. 
It is also possible that patients received empiric therapy for 
CDI without a test being performed. However, the same 
survey of Durham County physicians indicated this was 
not a common practice. Some potential case-patients were 
categorized as unknowns when little or no medical records 
were available. We did not collect data on laboratory test-
ing performed for any other enteric pathogens besides C. 
difﬁ  cile nor did we perform cultures for C. difﬁ  cile, and 
therefore no isolates were available.
Instead, case conﬁ  rmation was limited to toxin im-
munoassay testing using the C. DIFFICILE TOX A/B II 
TECHLAB test. In an independent review (32), the sensi-
tivity of this test was 83.3% and the speciﬁ  city was 98.7%. 
To address the concern of inadequate sensitivity in the 
toxin immunoassay and to avoid any misclassiﬁ  cation bias 
in our case–control studies, we excluded controls who had 
diarrhea. Despite the high speciﬁ  city of this test, there are 
valid concerns that if a low-prevalence population, such 
as relatively asymptomatic persons without prior antimi-
crobial drug exposures, is tested, the likelihood of a false-
positive result may be unacceptably high. Although this is 
an insurmountable obstacle to a retrospective analysis of 
current clinical testing practice for CDI, the fact that all 
study laboratories had rejection criteria to prevent testing 
formed stool, near uniform medical record documentation 
of diarrhea (i.e., patients with documented absence of di-
arrhea were excluded), and a median duration of diarrhea 
symptoms of 1 week suggests a reasonable pretest likeli-
hood of CDI among these patients.
Another limitation was that few interviews were per-
formed with case-patients. However, the adequacy of re-
cords indicating exposure to inpatient healthcare or anti-
microbial drugs was veriﬁ  ed among 53 case-patients who 
were interviewed by telephone. Only 1 case-patient was 
reclassiﬁ  ed on the basis of an undocumented healthcare 
exposure, which was discovered during the interview pro-
cess. Five of the 11 case-patients for whom antimicrobial 
drug exposure was not identiﬁ  ed in their available medi-
cal records reported antimicrobial drug use. However, 3 
of these were VA case-patients for whom medical records 
did not document such use, which suggests that some pa-
tients may have been mistaken about their antimicrobial 
drug exposure.
Another limitation is that our use of outpatient controls 
for the VA case–control study may have resulted in bias 
toward the null with regard to outpatient healthcare-related 
risk factors. Although we attempted to contact >400 candi-
date controls from the voter registration list for the Durham 
County case–control study, we encountered difﬁ  culty in 
reaching persons by phone and eliciting their participation. 
This resulted in only 48 controls being available and lim-
ited the power of this analysis.
In summary, CA-CDI is a relatively common clinical 
diagnosis. Although we did not determine the incidence in 
children, we found that CA-CDI in Durham County has a 
spectrum of disease that involves predominantly middle 
and older-aged women with underlying illness. As pre-
viously documented in other recent studies, this disease 
may, and commonly does, occur in patients without recent 
antimicrobial drug exposure. Nonetheless, antimicrobial 
drug exposure use remains the most important modiﬁ  able 
risk factor, suggesting prudent antimicrobial use remains 
a prominent public health prevention strategy. Further re-
search into the incidence, sources, and risk factors for CA-
CDI should be an ongoing public health priority.
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